Devran COŞKUN, Rahmi CANBAR, Burak DİK, Ayşe ER, Enver YAZAR, Yasemin KORKMAZ

Marbofloksasinin kardiyotoksik etkilerinin araştırılması

Amaç: Mevcut araştırmanın öncelikli amacı marbofloksasinin kardiyotoksiketkilerini kalp hasarı belirteçleri olan serum troponin I,kreatin kinaz-MB (CK-MB), laktat dehidrogenaz (LDH) ve aspartataminotransferaz (AST) düzeyleri ölçümü ile belirlemektir. Ayrıcakaraciğer fonksiyon [alkalen fosfotaz (ALP), alanin aminotransferaz(ALT), gamma glutamiltransferaz (GGT), total protein], böbrek fonksiyon[kan üre nitrojen (BUN), kreatinin] ve hemogram [akyuvar(WBC), alyuvar (RBC), platelet, hemoglobin, hemotokrit] parametreleriüzerine etkisini belirlemektir.Gereç ve Yöntem: Araştırmada 10 adet Merinos ırkı erkek tokluyamarbofloksasin (10 mg/kg/gün, deri altı) 14 gün süresince uygulandı.0. (Kontrol), 1., 3., 5., 7., 9., 11., 13. ve 15. günler kan örneklerialındı. Koyun spesifik serum CK-MB ve troponin I düzeyleri ELISAokuyucusunda, serum LDH, AST, ALT, ALP, GGT, total protein, kreatininve BUN değerleri otoanalizörde ve hemogram parametreleri kanhücresi sayım cihazında belirlendi.Bulgular: Marbofloksasin uygulamasının kalp hasarı belirteçi troponinI düzeyinde istatistiki olmayan (P>0,05), LDH ve AST düzeylerindeise istatistiki (P0,05), böbrek fonksiyonparametrelerinden BUN düzeyinde artışlara (P

PDF

___

Altan F, Corum O, Corum DD, Atik O, Uney K, 2018a. Pharmacokinetics and bioavailability of marbofloxacin in lambs following administration of intravenous, intramuscular and subcutaneous. Small Rum Res, 159, 5-10.
Altan F, Corum O, Corum DD, Uney K, 2018b. Effects of different doses marbofloxacin on biochemical and hematological parameters in sheep. Eurasian J Vet Sci, 34, 71-76
Briasoulis A, Agarwal V, Pierce WJ, 2011. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology, 120, 103-110.
Bulbul A, 2013. Normal hematological values, in: Sheep & Goat Hand Book, Ed: Elmas E, Billur Press, Konya, Turkey, pp: 509-515.
Corum O, Dik B, Bahcivan E, Eser H, Er A, Yazar E, 2016. Cardiac safety of gamithromycin in ewes. Eurasian J Vet Sci, 32, 242-245.
Corum O, Er A, Dik B, Eser H, Bahcivan E, Yazar E, 2015. Determination of the safety of tulathromycin in sheep. Eurasian J Vet Sci, 31, 152-157.
Coskun D, Parlak K, Dik B, Faki HE, Bahcivan E, Yazar E, Er A, 2018. Effect of enrofloxacin on the joint fluid/blood oxidative status and organ damage markers. An Res Rev Biol, 25, 1-7.
Danese E, Montagnana M, 2016. An historical approach to the diagnostic biomarkers of acute coronary syndrome. Ann Transl Med, 4, 194.
Hallen J, 2012. Troponin for the estimation of infarct size: what have we learned? Cardiology, 121, 204-212
Heidelbaugh JJ, Holmstrom H, 2013. The perils of prescribing fluoroquinolones. J Fam Pract, 62, 191-197.
Jackson MA, Schutze GE, 2016. The use of systemic and topical fluoroquinolones. Pediatrics, 138(5): e20162706.
Liu HH, 2010. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf, 33, 353-369.
Liu X, Ma J, Huang L, Zhu W, Yuan P, Wan R, Hong K, 2017. Fluoroquinolones increase the risk of serious arrhythmias: A systematic review and meta-analysis. Medicine, 96(44): e8273.
Lopes DI, Sousa MG, Ramos AT, Maruo VM, 2016. Cardiotoxicity of Senna occidentalis in sheep (Ovis aries). Open Vet J, 6, 30-35.
Lorenzutti AM, Litterio NJ, Himelfarb MA, Zarazaga MDP, San Andres MI, De Lucas JJ, 2017. Pharmacokinetics, milk penetration and PK/PD analysis by Monte Carlo simulation of marbofloxacin, after intravenous and intramuscular administration to lactating goats. J Vet Pharmacol Ther, 40, 629-640.
Martinez M, McDermott P, Walker R, 2006. Pharmacology of the fluoroquinolones: a perspective for the use in domestic animals. Vet J, 172, 10-28.
Obe IDA, 2007. Appendices, in: Disease of Sheep, Ed: Obe IDA, Backwell publishing, Oxford, UK, pp: 601-604.
O'Brien PJ, 2008. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology, 245, 206-218.
Orfanou D, Fragkou Ι, Fthenakis G, Mavrogianni V, 2012. Control of liver abscesses in lambs by using marbofloxacin. J Hellen Vet Med Soc, 63, 213-221.
Ramachandran G, Swaminathan S, 2015. Safety and tolerability profile of second-line anti-tuberculosis medications. Drug Saf, 38, 253-269.
Satoh Y, Sugiyama A, Chiba K, Tamura K, Hashimoto K, 2000. QT-prolonging effects of sparfloxacin, a fluoroquinolone antibiotic, assessed in the in vivo canine model with monophasic action potential monitoring. J Cardiovasc Pharmacol, 36, 510-515.
Sharma PC, Jain A, Jain S, 2009. Fluoroquinolone antibacterials: A review on chemistry, microbiology and therapeutic prospects. Acta Pol Pharm, 66, 587-604.
Shen J, Qian JJ, Gub JM, Hu XR, 2012. Marbofloxacin. Acta Cryst, 68, 998-999.
Skoufosa J, Christodoulopoulos G, Fragkoub LA, Tzorab A, Gougoulis DA, Orfanou DC, Tsiolaki K, Fthenakis GC, 2017. Efficacy of marbofloxacin against respiratory infections of lambs. Small Rumin Res, 71, 304-309.
Stahlmann R, Lode H, 2010. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging, 27, 193- 209.
Turgut K, 2000. Veterinary Clinic Laboratory Diagnosis, second press, Bahcivanlar Press, Konya, Turkey, pp: 17-123, 202-257, 320-366.
Yazar E, 2018a. Veteriner İlaç ve Aşı A’dan Z’ye, Atlas yayın dağıtım, Konya, Türkiye, p: 152.
Yazar E, 2018b. Kemoterapötikler, in: Veteriner İlaç Rehberi ve Tedavi El Kitabı, Ed: Yazar E, Nobeltip, Istanbul, Türkiye, pp: 85-161.